Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DONEPEZIL HYDROCHLORIDE
Pliva Pharma Limited
5 Milligram
Film Coated Tablet
2009-11-27
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Donepezil Teva 5 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg donepezil hydrochloride. Excipient(s): Each 5 mg film-coated tablet contains 56.95mg of lactose (as monohydrate) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Donepezil Teva 5 mg film-coated tablets are white to off-white, round, biconvex film-coated tablets, with beveled edges and debossed 'TEVA' on one side and 738 on the other side 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Donepezil Teva film-coated tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use. For doses not realisable/practicable with this strength other strengths of this medicinal product are available. _ADULTS/ELDERLY:_ Treatment is initiated at 5 mg/day (once-a-day dosing). Donepezil hydrochloride should be taken orally, in the evening, just prior to retiring. The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of donepezil hydrochloride can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials. Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil hydroch Read the complete document